RxDoctor Payments Data

Sandra Rodriguez

Family · Shavano Park, TXNPI 1366516254

Payments from drug & device makers

$18,758in general payments, 2019–2025

Across 619 payments — averaging $30.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Dexcom, Inc.$2K
  • Novo Nordisk$2K
  • Lilly USA, LLC$2K
  • AstraZeneca$1K
  • Eli Lilly$1K
  • Amgen$974
  • plus $10K from 51 others

What the payments were for

  • Travel & lodging$8525%
  • Food & beverage$17,69694%
  • Education$2101%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$18,758 in reported general payments places this provider in the 95th percentile of 15,456 family providers in Texas.

See all family providers in Texas

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide190$257,259
OzempicSemaglutide92$142,333
FarxigaDapagliflozin Propanediol105$116,639
JardianceEmpagliflozin58$80,680
Synjardy XrEmpagliflozin/Metformin Hcl40$57,528
TrulicityDulaglutide33$45,463
Tresiba Flextouch U-100Insulin Degludec32$41,658
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/726$32,637
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog19$29,264
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog23$27,769
Xigduo XrDapaglifloz Propaned/Metformin20$16,915
JanuviaSitagliptin Phosphate19$16,914
VascepaIcosapent Ethyl13$11,868
SynthroidLevothyroxine Sodium72$6,518
Icosapent Ethyl15$6,119

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity, Humalog$1,518$308,554237 claims
Novo NordiskOzempic$1,774$142,33392 claims
Boehringer IngelheimJardiance, Synjardy Xr$318$138,20898 claims
AstraZenecaFarxiga$1,382$116,639105 claims
MerckJanuvia$45$16,91419 claims
AbbVieSynthroid$395$6,51872 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium, Unithroid$44$2,538176 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 15,456 family providers in Texas.

Other family in Shavano Park

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →